Hydromethylthionine Mesylate

Hydromethylthionine, also known as LMTM and Leucomethylene Blue, is a apotent tau aggregation inhibitor for the treatment of Alzheimer's disease (AD) and frontotemporal dementia. Hydromethylthionine showed pharmacological activity on brain structure and function as both monotherapy and as an add-on to symptomatic treatment in certain patients with Alzheimer’s disease. Leucomethylene blue (hydrobromide) is a common reduced form of Methylene Blue, Methylene Blue is a member of the thiazine class of dyes.


Cat. No.: EX-A1927	Purity: >98%

	Chemical structure of Hydromethylthionine Mesylate

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
250mg	550	In-stock
500mg	785	In-stock
1g	1185	In-stock
5g	Get quote	In-stock

Send PO to E-mail:order@excenen.com; or Fax:+86 020 81619670

Discount Request


Synonyms	Leucomethylene blue Mesylate
Synonyms 2	TRx0237 Mesylate
CAS No.	1236208-20-0
Purity	>98%
Formula	C18H27N3O6S3
Mol Weight	477.618
Appearance	solid powder
Solubility	Soluble in DMSO
Shelf Life	>2 years if stored properly
Storage	Powder -20℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Shiells H, Schelter BO, Bentham P, Baddeley TC, Rubino CM, Ganesan H, Hammel J, Vuksanovic V, Staff RT, Murray AD, Bracoud L, Wischik DJ, Riedel G, Gauthier S, Jia J, Moebius HJ, Hardlund J, Kipps CM, Kook K, Storey JMD, Harrington CR, Wischik CM. Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia. J Alzheimers Dis. 2020;75(2):501-519. doi: 10.3233/JAD-191173. PMID: 32280089; PMCID: PMC7306898. [2]. Riedel G, Klein J, Niewiadomska G, Kondak C, Schwab K, Lauer D, Magbagbeolu M, Steczkowska M, Zadrozny M, Wydrych M, Cranston A, Melis V, Santos RX, Theuring F, Harrington CR, Wischik CM. Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model. Curr Alzheimer Res. 2020;17(3):285-296. doi: 10.2174/1567205017666200224120926. PMID: 32091331; PMCID: PMC7403648. [3]. Hashweh NN, Bartochowski Z, Khoury R, Grossberg GT. An evaluation of hydromethylthionine as a treatment option for Alzheimer's disease. Expert Opin Pharmacother. 2020 Apr;21(6):619-627. doi: 10.1080/14656566.2020.1719066. Epub 2020 Feb 8. PMID: 32037892. [4]. Schelter BO, Shiells H, Baddeley TC, Rubino CM, Ganesan H, Hammel J, Vuksanovic V, Staff RT, Murray AD, Bracoud L, Riedel G, Gauthier S, Jia J, Bentham P, Kook K, Storey JMD, Harrington CR, Wischik CM. Concentration- Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer's Disease. J Alzheimers Dis. 2019;72(3):931-946. doi: 10.3233/JAD-190772. PMID: 31658058; PMCID: PMC6918900.
CoA	CoA of Hydromethylthionine Mesylate

Smiles:	CS(O)(=O)=O.CS(O)(=O)=O.CN(C)C1=CC2=C(NC3=CC=C(C=C3S2)N(C)C)C=C1


		Search